Top Banner Top Banner

1. American Cancer Society. Lung Cancer, 2011.

2. Stinchcombe TE, et al. Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 2007;26:3691-3698.

3. Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer. J Clin Oncol 2009;27:1227-1234.

4. Patel JD, Hensing TA, Radenmaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first line therapy for non-squamous non-small cell lung cancer. J Clin Oncol 2009;27:3284-3289.

5. Hainsworth et al. Bevacizumab in combination with erlotinib compared with erlotinib alone for the treatment of advanced NSCLC after failure of standard first-line chemotherapy (BETA-Lung). Thoracic Oncol 2008;3(11)Suppl. 4: S302.

6. Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28 (15S suppl): Abstr 7526.

7. Kim ES, Herbst RS, Moon J, et al. SWOG 0536: Phase II trial of carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab in advanced non-small cell lung cancer. J Thoracic Oncol 2008;3(11):Suppl.4, Abstr. 9.

8. Scagliotti G, Vynnychenko I, Ichinose Y, et al. An international, randomized, placebo-controlled, double-blind phase III trial (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced non-squamous non-small cell lung cancer. J Clin Oncol 2011;29(suppl;abstr LBA7512).

9. Huang J, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockage. Proc Nat Acad Sci 2003; 100 (13): 7785-7790.

10. NCT00532155. A study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small cell lung cancer (VITAL). Accessed on June 24, 2011.

11. Camidge DR, Ballas MS, Dubey S, et al. A phase II open-label study of ramucirumab (IM-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIb/IV non-small cell lung cancer. 2010 ASCO annual meeting. Abstract 7588. J Clin Oncol 2010; 28: 15s (suppl; abstr 7588).

12. NCT01168973. A study in second-line non-small-cell lung cancer. Accessed June 7, 2011.

13. Boehringer Ingelheim corporate website. Accessed on July 6, 2011.

14. System ENABLEā„¢.

Last updated March 1, 2012